Mitra Shavakhi
1* 
, Agha Wajdan Baqir
2 1 Nickan Research Institute, Isfahan, Iran
2 Department of Pathology, University of Mississippi Medical Center, Jackson, Mississippi, United States
Abstract
IgA nephropathy is a common glomerulonephritis with variable clinical outcomes. The optimal treatment for this condition remains uncertain, and corticosteroid therapy is reserved for patients unresponsive to supportive treatment. The histopathologic examination has a significant role in the diagnosis and prognosis of IgA nephropathy, but its role in the initiation of corticosteroid therapy is still under debate. Recently, targeted release formulation (TRF)-budesonide has emerged as a promising treatment due to its localized delivery to the gut and low systemic adverse effects. This brief review aims to assess recent advancements in IgA nephropathy management, focusing on applying Oxford classification in guiding corticosteroid therapy.
Implication for health policy/practice/research/medical education:
Targeted release formulation-budesonide is a novel formulation of budesonide-corticosteroid for IgA nephropathy treatment. By incorporating histopathological features, the MEST-C score provides clinicians with valuable information for identifying patients likely to benefit from corticosteroid therapy.
Please cite this paper as: Shavakhi M, Baqir AW. Advances in IgA nephropathy management, from pathological insights to personalized treatment. J Nephropathol. 2023;12(3):e21480. DOI: 10.34172/jnp.2023.21480.